Immunome (IMNM) Operating Expenses (2019 - 2026)

Immunome has reported Operating Expenses for 8 years, with the latest figure at $59.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 24.74% year-over-year to $59.3 million; the trailing twelve-month figure through Mar 2026 stood at $242.8 million (up 6.0% YoY), and the FY2025 full-year result was $231.1 million, down 26.61% from the prior year.
• Operating Expenses for Q1 2026 stood at $59.3 million, down from $72.9 million in the prior quarter.
• The five-year high for Operating Expenses was $133.3 million in Q1 2024, with the low at $6.8 million in Q1 2023.
• Historically, Operating Expenses has averaged $45.0 million across 5 years, with a median of $47.6 million in 2025.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 1850.67% — and 2025, when it sank 64.33%.
• Immunome's Operating Expenses stood at $7.8 million in 2022, then jumped by 1164.66% to $98.5 million in 2023, then retreated by 12.97% to $85.7 million in 2024, then dropped by 14.99% to $72.9 million in 2025, then decreased by 18.57% to $59.3 million in 2026.
• The last three Operating Expenses figures came in at $59.3 million (Q1 2026), $72.9 million (Q4 2025), and $60.1 million (Q3 2025), per Business Quant data.